Drug intelligence / Profile preview

WU-WEI BAO-GAN WAN

Development stage: Unknown
Lead developer: Qingdao Hospital of Chinese Medicine
Administration: Oral

Overview

WU-WEI BAO-GAN WAN is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Qingdao Hospital of Traditional Chinese Medicine. It is specifically designed for the treatment of non-alcoholic fatty liver disease (NAFLD), particularly in patients presenting with TCM syndromes of liver stagnation and spleen deficiency, combined with liver and kidney Yin deficiency and blood stasis. The name translates to "Five-Flavor Liver-Protecting Pill," which may refer to the inclusion of *Schisandra chinensis* (Wu Wei Zi) or the five flavors of TCM. The drug has been evaluated in a Phase 1 clinical trial in China to assess its clinical efficacy, safety, and TCM mechanisms compared to polyene phosphatidyl choline.

Other names: Wuwei Baogan WanWuwei Baogan Pills

Targets

PXR (Pregnane X receptor)

Beyond the preview

Go deeper on WU-WEI BAO-GAN WAN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WU-WEI BAO-GAN WAN.

Explore the full profile